Evren Alici, MD, PhD
Evren Alici, MD, PhD
Department of Medicine, Karolinska Institutet
ki.se üzerinde doğrulanmış e-posta adresine sahip
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Natural killer cell‐based immunotherapy in cancer: current insights and future prospects
T Sutlu, E Alici
Journal of internal medicine 266 (2), 154-181, 2009
2622009
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
E Alici, T Sutlu, B Björkstrand, M Gilljam, B Stellan, H Nahi, HC Quezada, ...
Blood, The Journal of the American Society of Hematology 111 (6), 3155-3162, 2008
1882008
Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity
CIM Dahlberg, D Sarhan, M Chrobok, AD Duru, E Alici
Frontiers in immunology 6, 605, 2015
1562015
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor
T Sutlu, B Stellan, M Gilljam, HC Quezada, H Nahi, G Gahrton, E Alici
Cytotherapy 12 (8), 1044-1055, 2010
1032010
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study
L Barkholt, E Alici, R Conrad, T Sutlu, M Gilljam, B Stellan, B Christensson, ...
Immunotherapy 1 (5), 753-764, 2009
1032009
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
KJ Malmberg, YT Bryceson, M Carlsten, S Andersson, A Björklund, ...
Cancer Immunology, Immunotherapy 57 (10), 1541-1552, 2008
1032008
Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy
T Sutlu, S Nyström, M Gilljam, B Stellan, SE Applequist, E Alici
Human gene therapy 23 (10), 1090-1100, 2012
892012
Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model
E Alici, KV Konstantinidis, T Sutlu, A Aints, G Gahrton, HG Ljunggren, ...
Experimental hematology 35 (12), 1839-1846, 2007
662007
Advances in clinical NK cell studies: donor selection, manufacturing and quality control
U Koehl, C Kalberer, J Spanholtz, DA Lee, JS Miller, S Cooley, M Lowdell, ...
Oncoimmunology 5 (4), e1115178, 2016
652016
Towards an advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality and safety data
JP Martins, JM Santos, JM Almeida, MA Filipe, MVT de Almeida, ...
Stem cell research & therapy 5 (1), 9, 2014
552014
The role of CXC chemokine receptors 1–4 on immune cells in the tumor microenvironment
KH Susek, M Karvouni, E Alici, A Lundqvist
Frontiers in immunology 9, 2159, 2018
542018
Clinical impact of chromosomal aberrations in multiple myeloma
H Nahi, T Sutlu, M Jansson, E Alici, G Gahrton
Journal of internal medicine 269 (2), 137-147, 2011
462011
The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment
K Uttervall, AD Duru, J Lund, J Liwing, G Gahrton, E Holmberg, J Aschan, ...
PLoS One 9 (7), e101819, 2014
412014
Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells
KV Konstantinidis, E Alici, A Aints, B Christensson, HG Ljunggren, ...
Experimental hematology 33 (2), 159-164, 2005
412005
Efficient gene transfer into primary human natural killer cells by retroviral transduction
H Guven, KV Konstantinidis, E Alici, A Aints, M Abedi-Valugerdi, ...
Experimental hematology 33 (11), 1320-1328, 2005
402005
Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma
E Alici, KV Konstantinidis, A Aints, MS Dilber, M Abedi-Valugerdi
Experimental hematology 32 (11), 1064-1072, 2004
382004
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population
J Liwing, K Uttervall, J Lund, A Aldrin, C Blimark, K Carlson, J Enestig, ...
British journal of haematology 164 (5), 684-693, 2014
372014
IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers.
E Alici
Current opinion in molecular therapeutics 12 (6), 724, 2010
352010
TK. 007: A novel, codon-optimized HSVtk (A168H) mutant for suicide gene therapy
E Preuß, A Treschow, S Newrzela, D Brücher, K Weber, U Felldin, E Alici, ...
Human gene therapy 21 (8), 929-941, 2010
312010
Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma
H Nahi, M Chrobok, C Gran, J Lund, A Gruber, G Gahrton, P Ljungman, ...
PloS one 14 (2), e0211927, 2019
282019
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20